The mechanism is not well understood; it probably inhibits DNA replication, but also has affinity to RNA. The drug is known to change the structure of kinetoplast DNA in the Trypanosoma cruzi parasite, which causes Chagas' disease. In particular, kinetoplasts from parasites exposed to the drug have more densely linked minicircles, leading to the formation of fibers within the networks.
Side effects
Acute side effects include vomiting, diarrhea, and hypotension (low blood pressure). Diminazen can harm the liver, kidneys and brain, which is potentially life-threatening; camels are especially susceptible to these effects.
Resistance
Drug resistance, or at least evidence of treatment failure, has been reported in several countries in Africa. For example, the Gibe River Valley in southwest Ethiopia showed universal resistance between July 1989 and February 1993. This likely indicates a permanent loss of function in this area against the tested target, T. congolense isolated from Boran cattle.
↑Zuma AA, Cavalcanti DP, Zogovich M, Machado AC, Mendes IC, Thiry M, etal. (February 2015). "Unveiling the effects of berenil, a DNA-binding drug, on Trypanosoma cruzi: implications for kDNA ultrastructure and replication". Parasitology Research. 114 (2): 419–430. doi:10.1007/s00436-014-4199-8. hdl:2268/173546. PMID25349143.
↑FAO (2022). Expert consultation on the sustainable management of parasites in livestock challenged by the global emergence of resistance - Part 2: African animal trypanosomosis and drug resistance – a challenge to progressive, sustainable disease control, 9–10 November 2021. FAO Animal Production and Health Report No. 18. Rome: FAO. doi:10.4060/cc2988en. ISBN978-92-5-137217-3.